Conference Coverage: ASH 2024 – Focus on Leukemia
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
December 13, 2024
Faculty Chair
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Aaron Logan, MD, PhD
University of California San Francisco, CA, USA
Naval Daver, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil
Queen Elizabeth Hospital, Birmingham, UK
Valeria Santini, MD
University of Florence, Italy
Josep-Maria Ribera, MD, PhD
Catalan Institute of Oncology, Barcelona, Spain
REPORT SNAPSHOT
- Advances in Acute Lymphoblastic Leukemia (ALL): Newly Diagnosed
- Advances in ALL: Relapsed/Refractory
- New Developments in Myelodysplastic Syndromes (MDS)
- Advances in Acute Myeloid Leukemia (AML): Newly Diagnosed
- Advances in AML: Relapsed/Refractory
